After its drug Palifosfamide failed to show efficacy in a phase 3 sarcoma trial, shares of Ziopharm Oncology (NASDAQ: ZIOP ) fell through the floor, dropping by more than 66%. Do shareholders have any hope of a recovery? In this video, Motley Fool health-care analyst David Williamson takes us through what the cash situation looks like at Ziopharm, where the company will be shifting its focus next, and what, if any, hope remains.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.